Spinal muscular atrophy is a neurological condition that affects an individual’s movement. The rare genetic condition causes the muscles to weaken due to improper functioning of the spinal cord and brainstem cells, and it is the leading genetic cause of infant mortality. Despite its prominence, there is a general lack of awareness about this degenerative disorder. This article tries to bridge the gap by discussing the types and common symptoms of the condition:

What is spinal muscular atrophy?
Spinal Muscular Atrophy (SMA) is a group of hereditary disorders that affect movement. The condition causes muscle wasting and weakness, mostly due to the loss of nerve cells present in the brain stem and spinal cord. It is inherited in an autosomal recessive trait, which means an individual must receive the defective gene from both parents (SMA carriers) to develop the disorder.
The severity varies based on the type of SMA, with type 0 being the rarest and most severe form that develops during pregnancy. Milder forms of SMA develop during childhood (type 3) and adulthood (type 4).

What are the symptoms of SMA?
SMA symptoms depend on the type of the neuromuscular disease. There are five basic types, each of which manifests differently. Here are some of the symptoms that manifest with each type:

• Type 0
  This is the rarest form of SMA, and it develops in babies while they are still in the womb. Common signs and symptoms of SMA type 0 include weak muscle tone, joint troubles, and weak muscles for breathing.
• Type 1
  Another severe form of SMA, type 1 can leave an affected infant unable to support their head or sit without support. Swallowing trouble, breathing difficulties, and floppy arms and legs are also common among babies with this type of SMA.
• Type 2
  This type affects babies of 6-18 months and causes moderate to severe symptoms that mostly affect the legs. This can hinder movement, but babies can sit and stand without help.
• Type 3
  The symptoms for this type occur between 2-17 years of age, and it is the mildest form of SMA. Children with this type can stand and walk without support but may experience trouble running, walking up the stairs, or getting up from a chair.
• Type 4
  This SMA type begins in adulthood, and the symptoms generally last through life. Common symptoms include muscle weakness, twitching, and breathing troubles.

Treatment options

SPINRAZA® (nusinersen)
SPINRAZA® is an FDA-approved prescription suggested for the management of SMA symptoms. The formula is designed to address the source of muscle weakness triggered by a deficiency of proteins necessary for motor neuron function. SPINRAZA® promotes the production of SMN proteins genetically designed to overcome muscle weakness and other motor problems.

ZOLGENSMA® (onasemnogene abeparvovec-xioi)
ZOLGENSMA® (onasemnogene abeparvovec-xioi) helps address motor neuron problems among young children and infants triggered by the onset of SMA. The treatment option is designed to replace the SMN1 gene function and help restore the production of specific proteins that control motor functions. It helps lower the risk of further progression.

Evrysdi® (risdiplam)
Evrysdi® (risdiplam) is an FDA-approved prescription for managing SMA symptoms, mainly muscle weakness and reduced motor control among children and adults. Evrysdi® (risdiplam) helps enable the production of SMN protein levels in the blood within the first four weeks of prescription.